NO20072494L - Fast farmasoytisk forbindelse som omfatter donepezil-hydroklorid - Google Patents

Fast farmasoytisk forbindelse som omfatter donepezil-hydroklorid

Info

Publication number
NO20072494L
NO20072494L NO20072494A NO20072494A NO20072494L NO 20072494 L NO20072494 L NO 20072494L NO 20072494 A NO20072494 A NO 20072494A NO 20072494 A NO20072494 A NO 20072494A NO 20072494 L NO20072494 L NO 20072494L
Authority
NO
Norway
Prior art keywords
donepezil hydrochloride
solid pharmaceutical
pharmaceutical compound
relates
composition
Prior art date
Application number
NO20072494A
Other languages
English (en)
Norwegian (no)
Inventor
Rok Zupet
Matej Rkolj
Miha Vrbinc
Berta Kotar-Jordan
Original Assignee
Krka Tovarna Zdravil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35464350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072494(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krka Tovarna Zdravil filed Critical Krka Tovarna Zdravil
Publication of NO20072494L publication Critical patent/NO20072494L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)
NO20072494A 2004-10-19 2007-05-15 Fast farmasoytisk forbindelse som omfatter donepezil-hydroklorid NO20072494L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004051055 2004-10-19
PCT/EP2005/011249 WO2006045512A1 (fr) 2004-10-19 2005-10-19 Composition pharmaceutique solide contenant du chlorhydrate de donepezil

Publications (1)

Publication Number Publication Date
NO20072494L true NO20072494L (no) 2007-07-02

Family

ID=35464350

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072494A NO20072494L (no) 2004-10-19 2007-05-15 Fast farmasoytisk forbindelse som omfatter donepezil-hydroklorid

Country Status (19)

Country Link
US (3) US20090130205A9 (fr)
EP (3) EP1811957B1 (fr)
JP (1) JP2008517022A (fr)
AT (1) ATE415148T1 (fr)
CA (1) CA2584547C (fr)
CY (1) CY1109956T1 (fr)
DE (1) DE602005011326D1 (fr)
DK (1) DK1811957T3 (fr)
EA (1) EA012220B1 (fr)
ES (1) ES2317313T3 (fr)
HR (1) HRP20090104T3 (fr)
NO (1) NO20072494L (fr)
PL (1) PL1811957T3 (fr)
PT (1) PT1811957E (fr)
RS (1) RS51271B (fr)
SI (1) SI1811957T1 (fr)
UA (1) UA83152C2 (fr)
WO (1) WO2006045512A1 (fr)
ZA (1) ZA200704023B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0515803D0 (en) * 2005-07-30 2005-09-07 Pliva Hrvatska D O O Intermediate compounds
DE102005060377A1 (de) 2005-12-16 2007-06-21 Ratiopharm Gmbh Pharmazeutische Zusammensetzung enthaltend Donepezilhydrochlorid, Tablette hieraus und Verfahren zu deren Herstellung
EP2037918A2 (fr) * 2006-05-15 2009-03-25 Acadia Pharmaceuticals Inc. Formules pharmaceutiques de pimavansérine
GB0614586D0 (en) * 2006-07-22 2006-08-30 Pliva Istrazivacki Inst D O O Pharmaceutical Formulation
EP2117611B1 (fr) * 2007-01-24 2014-07-30 Cook Medical Technologies LLC Produits médicaux inhibiteurs de pellicules biologiques
GR20070100405A (el) * 2007-06-26 2009-01-20 Genepharm �.�. Βελτιωμενες φαρμακοτεχνικες μορφες που περιεχουν αναστολεις της ακετυλοχοληνεστερασης και μεθοδοι παρασκευης αυτων
DE102007037932A1 (de) * 2007-08-11 2009-02-12 Alfred E. Tiefenbacher Gmbh & Co.Kg Donepezilhydrochlorid in amorpher Form enthaltende Tablette
DE102009041839A1 (de) * 2009-09-18 2011-03-24 Dolorgiet Gmbh & Co. Kg Donepezil-haltige Tabletten
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
EP2366378A1 (fr) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Formulations de donépézil à libération prolongée
DE102010010998A1 (de) * 2010-03-10 2011-09-15 Stada Arzneimittel Ag Feste pharmazeutische Zusammensetzung, umfassend Donepezil-Hydrochlorid der kristallinen polymorphen Form I
WO2012016708A1 (fr) 2010-08-06 2012-02-09 Ratiopharm Gmbh Forme pharmaceutique orale comportant la diméboline et le donézépil
JP6093707B2 (ja) * 2010-11-30 2017-03-08 ウィスタ ラボラトリーズ リミテッド 化合物製剤
EP2502620A1 (fr) 2011-03-24 2012-09-26 Krka Tovarna Zdravil, D.D., Novo Mesto Composition pharmaceutique solide comportant du donépézil
EP3102186B1 (fr) 2014-02-04 2021-01-27 Forest Laboratories Holdings Limited Compositions de donépézil et procédé de traitement de la maladie d'alzheimer
CN114272219B (zh) * 2021-12-30 2023-11-10 江苏豪森药业集团有限公司 一种盐酸多奈哌齐片及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813064D0 (en) * 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US4956182A (en) * 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
WO1997046526A1 (fr) * 1996-06-07 1997-12-11 Eisai Co., Ltd. Polymorphes stables d'hydrochlorure de 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methyl-piperidine), dit hydrochlorure de donepezil et procede pour leur production
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
SK285312B6 (sk) * 1996-06-07 2006-10-05 Eisai Co., Ltd. Polymorf (III) donepezil hydrochloridu, spôsob jeho výroby a terapeutický prostriedok s jeho obsahom
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
US6390821B1 (en) * 1997-02-07 2002-05-21 Princeton University Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
PT1054986E (pt) * 1998-02-19 2008-01-09 Sapporo Breweries Ácidos nucleicos isolados e purificados que compreendem um gene especificmante expresso em glândulas de lúpulo
ATE254928T1 (de) * 1999-03-31 2003-12-15 Eisai Co Ltd Stabilisierte zusammensetzung mit nootropen wirkstoffen
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PT1260215E (pt) * 2000-03-01 2009-09-03 Eisai R&D Man Co Ltd Comprimido de desintegração rápida que contém poli(álcool vinílico)
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
IN192180B (fr) * 2001-09-28 2004-03-06 Ranbaxy Lab
TWI231760B (en) * 2001-12-20 2005-05-01 Chugai Pharmaceutical Co Ltd Coated lozenge and manufacturing method thereof
SI21223A (sl) * 2002-06-19 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtska formulacija s stabiliziranim amorfnim donepezilijevim kloridom
IL150509A (en) 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
WO2004047793A1 (fr) * 2002-11-26 2004-06-10 Alk-Abelló A/S Produit pharmaceutique comprenant des allergenes
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
AU2003245029A1 (en) * 2003-04-16 2004-11-04 Hetero Drugs Limited Novel crystalline forms of donepezil hydrochloride
US20040265372A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics

Also Published As

Publication number Publication date
CA2584547C (fr) 2014-07-08
RS51271B (sr) 2010-12-31
DE602005011326D1 (de) 2009-01-08
WO2006045512A1 (fr) 2006-05-04
EP2039349A1 (fr) 2009-03-25
ATE415148T1 (de) 2008-12-15
US20090130205A9 (en) 2009-05-21
US20100317694A1 (en) 2010-12-16
CY1109956T1 (el) 2014-09-10
JP2008517022A (ja) 2008-05-22
HRP20090104T3 (hr) 2009-03-31
ZA200704023B (en) 2008-04-30
DK1811957T3 (da) 2009-03-30
US20120283291A1 (en) 2012-11-08
EA012220B1 (ru) 2009-08-28
EA200700673A1 (ru) 2007-10-26
EP1811957B1 (fr) 2008-11-26
CA2584547A1 (fr) 2006-05-04
PT1811957E (pt) 2009-01-27
US20080063705A1 (en) 2008-03-13
SI1811957T1 (sl) 2009-04-30
UA83152C2 (ru) 2008-06-10
EP2283811A1 (fr) 2011-02-16
EP1811957A1 (fr) 2007-08-01
PL1811957T3 (pl) 2009-05-29
ES2317313T3 (es) 2009-04-16

Similar Documents

Publication Publication Date Title
NO20072494L (no) Fast farmasoytisk forbindelse som omfatter donepezil-hydroklorid
DK1707562T3 (da) Krystallinsk v-form af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famaceutiske sammensætninger, som indeholder denne
NO20080243L (no) Substituerte arylpyrazoler til anvendelse mot parasitter
EA200970051A1 (ru) Антагонист рецептора il-8
WO2004074438A3 (fr) Antagonistes de ccr8
DK1695965T3 (da) Krystallinsk betaform af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famceutiske sammensætninger indeholdende denne
WO2004073619A3 (fr) Antagonistes du recepteur ccr8
DK1695709T3 (da) Krystalinsk gammad-form af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende denne
WO2007030361A3 (fr) Composes de benzimidazole thiophene
NO20074874L (no) Amorf lerkanidipinhydroklorid
WO2003086362A3 (fr) Comprimes d'hydrochlorure de bupropion stables
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
DK2407451T3 (da) N,N-substituerede 3-aminopyrrolidin-forbindelser anvendelige som monoamin-genoptagelseshæmmere
NO20091990L (no) Substituerte pyrazoler, sammensetninger inneholdende disse, fremgangsmate for fremstilling og anvendelse
NO20065046L (no) Krystallinsk polymorf av bazedoksifenacetat
NO20063944L (no) Piperidinylkarbonyl-pyrrolidiner og deres anvendelse som melanokortinagonister
NO20091331L (no) Nitrogenholdige substituerte heterocykler som blodplate ADP reseptorinhibitorer
PH12021550456A1 (en) Crystalline forms of a quinazole compound and its hydrochloride salts
TW200833371A (en) Process for solid formulations
WO2007108011A3 (fr) Procede de preparation de donepezile de grande purete
DK1761478T3 (da) En isoleret Atomoxetin urenhed, fremgangsmåde til fremstilling af Atomoxetin urenheder og deres anvendelse som referencestandarder
NO20090896L (no) Farmakokinetisk forbedrede forbindelser
WO2006020348A3 (fr) Polymorphes du chlorhydrate d'atomoxetine
NO20064884L (no) Kjemisk fremgangsmate og ny krystallinsk form

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application